Coliving vs HMO Investment: Which is Better? (UK Focus)

Understanding the UK Landscape

In the UK, coliving and HMOs (Houses in Multiple Occupation) share physical similarities, multiple unrelated residents sharing a property. But they differ significantly in target market, operations, pricing, and regulations.

Key Differences

Target Market

HMO: Budget-conscious tenants seeking affordable housing. Typically students and young workers. Longer stays (6-12 months), limited community expectations.

Coliving: Professionals willing to pay a premium for community, amenities, and convenience. All-inclusive pricing, curated experiences, and community management.

Pricing & Returns

HMO: £400-700/room/month in most UK cities. Yields: 8-14% gross. Lower operational costs but also lower revenue per room.

Coliving: £700-1,200/room/month in major cities. Yields: 6-10% gross. Higher revenue offset by higher operational costs (community management, events, amenities).

Regulations

HMO: Well-established regulatory framework. Mandatory HMO license for 5+ tenants, minimum room sizes, fire safety requirements, management standards.

Coliving: Falls under HMO regulations but often has additional planning requirements (sui generis use class). Some councils have specific coliving policies. Check our UK regulations guide for details.

Which Is Right for You?

Choose HMO if: You want a simpler operation, are comfortable with lower per-room revenue, prefer minimal community management, and want established regulatory clarity.

Choose coliving if: You want premium pricing, are willing to invest in community management and amenities, have a strong brand and marketing capability, and are targeting the growing professional renter market.

Frequently Asked Questions

Can I convert an HMO into coliving?

Yes, many UK coliving operators start by upgrading existing HMOs. The conversion typically involves improving communal spaces, adding amenities, rebranding, and hiring a community manager. Use our renovation cost estimator to budget the conversion.

Two routes through UK regulation

UK coliving and HMO investment are increasingly different planning, licensing, and operational models, even though both involve unrelated tenants sharing a property. The fork is on planning class.

HMO route: Property is classified C4 (small HMO, 3-6 unrelated occupants) or sui generis HMO (7+). Mandatory HMO licence under Housing Act 2004 for 5+ occupants. Local authority sets per-bedroom amenity ratios, fire safety standards, and licensing fees (£500-£1,100 per property). Article 4 directions in many boroughs (Hackney, Camden, Tower Hamlets, Newham) remove permitted development from C3 to C4, requiring full planning permission to convert.

Coliving route: For schemes of 50+ units, the London Plan Policy H16 created an explicit pathway for purpose-built large-scale shared living, classified as sui generis. Requires affordable provision and minimum room sizes (≥18 m²). Planning consent is full planning, not permitted development. Timeline 12-18 months from acquisition to consent; consultancy spend £100k+.

Capex and unit economics

HMO conversions: typically £15k-£30k per bed all-in capex including any compliance upgrades (fire suppression, EICR remediation, S257 works in pre-1991 conversions). Margins 18-28% depending on borough, ALOS, and operating sophistication.

Purpose-built H16 coliving: £150k-£300k per bed all-in (development cost + land + financing). Margins 22-32%. Higher absolute capex but lower per-bed operating cost at scale and stronger institutional capital access.

Investor return profiles

HMO portfolios trade at 6.0-7.5% cap rate, IRR 12-16% for value-add operators. Easier to scale 5-25 properties via master leases on existing C3/C4 stock. Suits boutique operators and family-office capital.

H16 large-scale coliving trades at 4.5-6.0% cap rate, IRR 10-14%. Single schemes are 50-500 beds, capital-intensive, operate on long-hold institutional capital. Suits Greystar, Round Hill, M&G-style allocations.

Which route should you take?

HMO if: you want to scale fast, can operate sub-£25k capex/bed, and target boroughs without Article 4. Coliving (H16) if: you have institutional capital, can absorb 18-month consenting timelines, and target purpose-built scale.

Related resources

• For London-specific regulatory deep-dive, see London Coliving Regulations.
• For the HMO licence application process, see How to Apply for an HMO Licence in London.
• For London market benchmarks (RevPAB, cap rate, OpEx), see Coliving in London.

The UK HMO regulatory reality check

Most first-time UK investors underestimate how regulatory friction reshapes the HMO-vs-coliving return profile. An HMO with five or more unrelated occupants forming more than one household triggers mandatory licensing under the Housing Act 2004, and selective or additional licensing schemes (Newham, Liverpool, Nottingham, parts of Manchester) extend that to smaller properties. Article 4 directions in cities like Bath, Oxford and large parts of London now strip permitted development rights, meaning a C3 to C4 conversion needs full planning permission, with refusal rates that EC operator interviews put at 30 to 55 percent in heavily restricted wards.

Coliving developments tend to fall under sui generis or large HMO (C4 plus or Sui Generis 7-plus bed) classifications, which face a different but often more navigable consent path because local planning authorities increasingly view purpose-built coliving as housing-supply positive. The trade-off is that sui generis schemes typically require 50-plus beds to clear viability, push you into BCO category fire compliance, and demand a managing agent with a documented operating model.

HMO vs coliving: the operator-grade benchmark table

The numbers below blend EC operator dataset values with publicly reported UK HMO indices (BVA BDRC, Paragon, Lendlord) for 2024-2025 stabilised assets. Treat them as planning ranges rather than guarantees.

Metric	Standard HMO (6-8 bed)	Coliving (40-120 bed)
Gross yield on cost	9-13%	7-10%
Net yield (post-opex)	5.5-8%	4.5-6.5%
Opex ratio (% of GOI)	28-38%	38-52%
Occupancy (mature)	92-97%	88-94%
Voids per turn (days)	10-18	4-9
Capex per bed (refurb)	£8k-£22k	£35k-£70k (new build)
Exit cap rate	7-9%	4.75-6.25%
Levered IRR (5-yr)	14-19%	13-22%

DSCR and debt sizing: what UK lenders will actually fund

Specialist HMO lenders (Paragon, Foundation, Shawbrook, LendInvest) typically size loans to a stressed DSCR of 1.25 to 1.4 at a pay-rate plus 1.5 to 2.0 percent stress, capping LTV at 70 to 75 percent on a value-as-HMO basis. EC operator interviews flag that many investors over-borrow against the market-value-with-vacant-possession (MV-VP) figure only to discover the bank refinances on the lower investment value (IV) at year two, triggering equity top-ups.

Coliving stabilised assets are still a thin debt market in the UK. Most institutional capital prefers BTR or PBSA debt facilities, and coliving sponsors have been pushed toward club deals with challenger banks, family offices, or forward-funding from REITs. Typical terms in 2024-2025: 55 to 65 percent LTC, DSCR covenants of 1.30 to 1.50, ICR covenants of 1.75 to 2.00, and interest reserves of 6 to 12 months.

Tax reality: what HMRC actually allows

• Section 24 finance cost restriction still applies to individual landlords on residential property. HMOs held personally lose full interest deductibility and only receive a 20 percent basic-rate tax reducer. Most serious HMO investors now operate via an SPV limited company to preserve full interest deductibility.
• Capital allowances on communal areas of qualifying HMOs and coliving schemes can be material. EC interviews with quantity surveyors suggest 8 to 14 percent of qualifying refurb capex on HMOs and 15 to 22 percent of new-build coliving capex can be claimed under plant and machinery and integral features, with land remediation relief on brownfield sites stacking another 50 percent uplift.
• VAT: HMOs and standard coliving are exempt residential supplies, meaning input VAT on refurb is generally not recoverable. The exception is zero-rated new-build coliving, where recovery on construction costs can swing the development IRR by 200 to 400 bps.
• Stamp Duty Land Tax (SDLT): multiple-dwellings relief was abolished in June 2024, so coliving schemes with self-contained units no longer benefit from the per-unit averaging that previously cut SDLT bills meaningfully.

The investment committee questions you should rehearse

Whether you are pitching a single HMO refinance or a 90-bed coliving forward fund, UK IC committees focus on the same five questions. EC investor interviews suggest preparing one slide per question rather than relying on a master deck.

• Planning durability: is the consent C4, sui generis, or PDR-reliant, and what is the Article 4 risk over the 5-year hold?
• Demand evidence: granular catchment data, employer concentration within 30 minutes, and an indexed rent comparison versus 1-bed flats and PBSA in the same postcode sector.
• Operating model: in-house vs managing agent, full-time-equivalent staffing per 100 beds (industry mean 1.6 to 2.4), and a documented voids and turns SLA.
• Exit liquidity: which buyer pool absorbs the asset at year 5? HMOs sell to PRS portfolios; coliving to BTR funds and REITs that demand 100-plus beds, ESG-aligned EPC B-plus, and a 5-year operator track record.
• Downside scenario: a stress where occupancy drops to 80 percent, opex inflates 12 percent, and exit cap softens 100 bps. UK ICs increasingly require this be modelled at term-sheet stage rather than at credit committee.

The exit math: who buys UK HMO vs UK coliving at year 5

HMO exit is a deep, commoditised market. Buyers include other BTL landlords, BTL portfolio aggregators, family offices, and the occasional REIT acquiring small-ticket residential. Cap rates trade in a 7 to 9 percent band depending on location and EPC rating, and HMO exit transactions clear in 14 to 22 weeks at standard agency fees of 1.5 to 2.5 percent. EC operator interviews suggest novice investors over-estimate exit speed by 6 to 12 weeks, particularly in markets where stamp duty surcharges have softened domestic buyer demand.

Coliving exit, in contrast, runs to a concentrated buyer pool: BTR funds (Greystar, Get Living, Quintain), REITs (Empiric, Unite Students seeking diversification), specialist coliving funds, and forward-funding institutional capital. Each of these buyers demands 80-plus beds, EPC B or better, 3-year audited financials, a recognisable operator brand, and a documented operating playbook. Below those thresholds the exit pool collapses and discounts of 12 to 25 percent to expected cap rate are common. Sponsors raising capital should be able to name 3 to 5 specific exit buyers and the comparable transactions that anchor their cap rate assumption.